Opeyemi Olabisi

Dr. Opeyemi Olabisi


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2017 in Seminars in Nephrology
Verified
Journal Article
Closed access
OOOpeyemi Olabisi
Opeyemi Olabisi
JHJohn F. Heneghan
John F. Heneghan

Keith NorrisKeith Norris
Keith Norris
OOOpeyemi Olabisi
Opeyemi Olabisi
MBM. Edwina Barnett
M. Edwina Barnett
YMYuan-Xiang Meng
Yuan-Xiang Meng
DMDavid Martins
David Martins
SNSusanne B. Nicholas
Susanne B. Nicholas
Chronic kidney disease (CKD) is a major non-communicable disease associated with high rates of premature morbidity and mortality. The prevalence of hypovitaminosis D (deficiency of 25(OH)D or 25D) is greater in racial/ethnic minorities and in patients with CKD than the general population. Low 25D is associated with bone and mineral disorders as well as immune, cardiometabolic and cardiovascular (CV) diseases. Thus, it has been suggested that low 25D contributes to the poor outcomes in patients with CKD. The prevalence of hypovitaminosis D rises progressively with advancing severity of kidney disease with over 30% of patients with CKD stage 3 and 70% patients with CKD stage 5 estimated to have low levels of 25D. This report describes several of the abnormal physiologic and counter-regulatory actions related to low 25D in CKD such as those in oxidative stress and inflammatory systems, and some of the preclinical and clinical evidence, or lack thereof, of normalizing serum 25D levels to improve outcomes in patients with CKD, and especially for the high risk subset of racial/ethnic minorities who suffer from higher rates of advanced CKD and hypovitaminosis D.

8 August 2015
Verified
Book Chapter
Closed access
PDF file
OOOpeyemi Olabisi
Opeyemi Olabisi
JBJoseph V. Bonventre
Joseph V. Bonventre